Cardiovascular effects and cardiopulmonary plasma gradients following intravenous infusion of neuropeptide Y in humans: Negative dromotropic effect on atrioventricular node conduction

Clinical Science

Volumn 103, Issue 6, 2002, Pages 535-542

  Ullman, Bengt ^a   Pernow, John ^b   Lundberg, Jan M ^c   Åström, Hans ^b   Bergfeldt, Lennart ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atrioventricular node; Electrophysiology; Haemodynamics; Humans; Neuropeptide Y

Indexed keywords

CALCIUM CHANNEL L TYPE; NEUROPEPTIDE Y; NORADRENALIN;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BOLUS INJECTION; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY SINUS BLOOD FLOW; HEART ATRIOVENTRICULAR NODE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HEART OUTPUT; HUMAN; HUMAN EXPERIMENT; LUNG ARTERY PRESSURE; MALE; NORMAL HUMAN; PRESSORECEPTOR; PRIORITY JOURNAL; VAGUS REFLEX;

EID: 0036916019     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs1030535     Document Type: Article

References (40)

1. Lundberg, J. M., Terenius, L., Hökfelt, T. and Goldstein, M. (1983) High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci. Lett. 42, 167-172
2. Allen, J. M., Gjörstrup, P., Björkman, J.-A., Ek, L., Abrahamsson, T. and Bloom, S. R. (1986) Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol. Scand. 126, 405-411
3. Gu, J., Polak, J. M., Adrian, T. E., Allen, J. M., Tatemoto, K. and Bloom, S. R. (1983) Neuropeptide tyrosine (NPY) - A major cardiac neuropeptide. Lancet ii, 1008-1010
4. Rudehill, A., Olcén, M., Sollevi, A., Hamberger, B. and Lundberg, J. M. (1987) Release of neuropeptide Y upon haemorrhagic hypovolemia in relation to vasoconstrictor effects in the pig. Acta Physiol. Scand. 131, 517-523
5. Ahlborg, G., Weitzberg, E., Sollevi, A. and Lundberg, J. M. (1992) Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y infusion in resting and exercising man. Acta Physiol. Scand. 145, 139-149
6. Ekblad, E., Edvinsson, L., Wahlestedt, C., Uddman, R., Håkanson, R. and Sundler, F. (1984) Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 8, 225-235
7. Lundberg, J. M. and Tatemoto, K. (1982) Pancreatic polypeptide family (APP, BPP, NPY and PPY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol. Scand. 116, 393-402
8. Lundberg, J. M., Franco-Cereceda, A., Hemsén, A., Lacroix, J. S. and Pernow, J. (1990) Pharmacology of noradrenaline and neuropeptide tyrosine (NPY)-mediated sympathetic co-transmission. Fund. Clin. Pharmacol. 4, 373-391
9. Allen, J. M., Bircham, P. M. M., Edwards, A. V., Tatemoto, K. and Bloom, S. R. (1983) Neuropeptide Y (NPY) reduces myocardial perfusion and inhibits the force of contraction of the isolated perfused rabbit heart. Regul. Pept. 6, 247-253
10. Franco-Cereceda, A., Lundberg, J. M. and Dahlöf, C. (1985) Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol. Scand. 124, 361-369
11. Komaru, T., Ashikawa, K., Kanatsuka, H, Sekiguchi, N., Suzuki, T. and Takishima, T. (1990) Neuropeptide Y modulates vasoconstriction in coronary microvessels in the beating canine heart. Circ. Res. 67, 1142-1151
12. Rudehill, A., Sollevi, A., Franco-Cereceda, A. and Lundberg, J. M. (1986) Neuropeptide Y (NPY) and the pig heart: Release and coronary vasoconstrictor effects. Peptides 7, 821-826
13. Clarke, J. G., Davies, G. J., Kerwin, R. et al. (1987) Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet i, 1057-1059
14. Potter, E. K. (1987) Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog. Neurosci. Lett. 77, 243-247
15. Kralios, F. A., Anderson, F. L., Hanson, G. R. and Kralios, A. C. (1995) Myocardial electrophysiologic effects of neuropeptide Y in dogs. Am. J. Physiol. 268, H2195-H2201
16. Bryant, S. M., Ryder, K. O. and Hart, G. (1991) Effects of neuropeptide Y on cell length and membrane currents in isolated guinea pig ventricular myocytes. Circ. Res. 69, 1106-1113
17. Du, X.-J. and Dart, A. M. (1999) Role of sympathoadrenergic mechanisms in arrhythmogenesis. Cardiovasc. Res. 43, 832-834
18. Lundberg, J. M., Martinsson, A., Hemsén, A. et al. (1985) Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem. Biophys. Res. Commun. 133, 30-36
19. Pernow, J., Lundberg, J. M., Kaijser, L. et al. (1986) Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin. Physiol. 6, 561-578
20. Ullman, B., Franco-Cereceda, A., Hulting, J., Lundberg, J. M. and Sollevi, A. (1990) Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J. Intern. Med. 228, 583-589
21. Hulting, J., Sollevi, A., Ullman, B., Franco-Cereceda, A. and Lundberg, J. M. (1990) Plasma neuropeptide Y on admission to a coronary care unit: Raised levels in patients with left heart failure. Cardiovasc. Res. 24, 102-108
22. Maisel, A. S., Scott, N. A., Motulsky, H. J. et al. (1989) Elevation of plasma neuropeptide Y levels in congestive heart failure. Am. J. Med. 86, 43-48
23. Ganz, W., Tamura, K., Marcus, H. S., Donoso, R., Yoshida, S. and Swan, H. J. C. (1971) Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation 44, 181-195
24. Bergfeldt, L., Melander, H. and Schenck-Gustavsson, K. (1991) Time-dependent variation in the cardiac conduction system assessed in young healthy individuals at weeks' interval: Implications for clinical trials. J. Am. Coll. Cardiol. 18, 792-800
25. Theodorsson-Norheim, E., Hemsén, A. and Lundberg, J. M. (1985) Radioimmunoassay for neuropeptide Y (NPY): Chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand. J. Clin. Lab. Invest. 45, 355-365
26. Pernow, J., Lundberg, J. M. and Kaijser, L. (1987) Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 40, 47-54
27. Morris, M. J., Cox, H. S. and Lambert, G. W. (1997) Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 29, 137-143
28. Bryant, S. M. and Hart, G. (1996) Effects of neuropeptide Y on L-type calcium current in guinea pig ventricular myocytes. Br. J. Pharmacol. 118, 1455-1460
29. McCullough, L. A., Egan, T. M. and Westfall, T. C. (1998) Neuropeptide Y inhibition of calcium channels in PC-12 pheochromocytoma cells. Am. J. Physiol. 274, C1290-C1297
30. Warner, M. R. and Levy, M. N. (1989) Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y. Circ. Res. 65, 1536-1546
31. Awad, S. J., Einstein, R., Potter, E. K. and Richardson, D. P. (1991) The effects of neuropeptide Y on myocardial contractility and coronary blood flow. Br. J. Pharmacol. 104, 195-201
32. Alboni, P., Malcarne, C., Pedroni, C., Masoni, A. and Narula, O. S. (1982) Electrophysiology of normal sinus node with and without autonomic blockade. Circulation 65, 1236-1242
33. Bergfeldt, L. Schenck-Gustavsson, K. and Dahlqvist, R. (1992) Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans. Cardiovasc. Drugs Ther. 6, 529-537
34. Englund, A., Bergfeldt, L. and Rosenqvist, M. (1998) Pharmacological stress testing of the His-Purkinje system in patients with bifascicular block. PACE Pacing Clin. Electrophysiol. 21, 1979-1987
35. Kennebäck, G., Bergfeldt, L., Vallin, H., Tomson, T. and Edhag, O. (1991) Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am. Heart J. 121, 1421-1429
36. Kennebäck, G., Bergfeldt, L. and Tomson, T. (1995) Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc. Drugs Ther. 9, 709-714
37. McDermott, J. R., Gibson, A. M., Boublik, J. and Biggins, J. A. (1992) Dipeptidylpeptidase IV initiates the degradation of neuropeptide Y in cardiac muscle membranes. Biochem. Soc. Trans. 4, 351S
38. Kaijser, L., Pernow, J., Berglund, B. and Lundberg, J. M. (1990) Neuropeptide Y is released together with noradrenaline from the human heart during exercise and hypoxia. Clin. Physiol. 10, 179-188
39. Warner, M. R., Senanayake, P. D., Ferrario, C. M. and Levy, M. N. (1991) Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ. Res. 69, 455-465
40. Tanaka, E., Mori, H., Chujo, M., Yamakawa, A. and Minhaz, U. (1997) Coronary vasoconstrictive effects of neuropeptide Y and their modulation by the ATP-sensitive potassium channel in anesthetized dogs. J. Am. Coll. Cardiol. 29, 1380-1389